Mereo BioPharma Group plc (MREO) stock
MREONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.29+0.01 (+5.39%)
Close on Nov 18, 2026Market cap $46.20MP/E –Yield –
Mereo BioPharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Mereo BioPharma's operating cash flow for the twelve months ending Sep 30, 2026 was -$22.09M. For fiscal 2025 it was -$30.97M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$30.97M | – |
| FY2024 | Dec 31, 2024 | -$32.83M | – |
| FY2023 | Dec 31, 2023 | -$21.13M | – |
| FY2022 | Dec 31, 2022 | -$48.82M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$4.05M | – |
| Q2 FY2026 | Jun 30, 2026 | -$6.04M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.31M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.68M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.31M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.42M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.52M | -382.8% |
| Q2 FY2024 | Jun 30, 2024 | -$7.90M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.99M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.79M | – |
| Q3 FY2023 | Sep 30, 2023 | $2.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.75M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.25M | – |
See a number that looks wrong?